Open MIND
June 26, 2026
Max Courtney
Substance use disorders (SUDs) represent a persistent global public health burden for which existing pharmacological and behavioral interventions show limited long-term efficacy across various patient populations (Sinha, 2011). Psilocybin-assisted therapy (PAT) has reemerged as a promising therapeutic treatment approach and has had renewed clinical interest with a growing amount of research...
American Journal of Medicine and Health Studies
June 26, 2026
Mehrdad F. Falavarjani
Substance use disorder (SUD) is typically treated using biomedical and psychosocial approaches that focus on reducing symptoms, regulating neurobehavioral processes, and managing behavior. While these approaches are effective for many individuals, they may not fully address the deeper challenges associated with long-term substance use, such as existential distress, disruptions in identity, and...
Pharmacological Reports
June 22, 2026
Magdalena Zaniewska
Serotonin (5-hydroxytryptamine; 5-HT) is a key neuromodulator involved in the regulation of mood, appetite, aggression, and impulse control. Dysregulation of central 5-HT function has been implicated in alcohol use disorder (AUD) and comorbid depression. This review summarizes clinical and preclinical evidence on the role of 5-HT in AUD development, heterogeneity, and treatment response....
Journal of Psychoactive Drugs
June 19, 2026
Carla J. Berg, Darcey M. Mccready, Cassidy R Loparco et al.
= 26.38, ~50% past-month cannabis use by design) completed an online survey. Multivariable regression assessed sociodemographics, mental health, and adverse childhood events (ACEs) in relation to: (1) past-year psychedelic use; and (2) among those reporting lifetime use: (a) lifetime microdosing and (b) use motives. Lifetime and past-year psychedelic use were 27.7% and 11.9% (commonly...
Leiden Repository
June 18, 2026
W.c. Naber
This dissertation explored the factors underlying the “waves” of cluster headache and investigated strategies to reduce disease burden and improve quality of life. The first part focused on disease mechanisms, prognosis, and patient experiences. Long-term remission was associated with episodic disease, later onset age, more painful attacks, and smoking cessation, suggesting a multifactorial...
Research Square
June 17, 2026
Martijn Arns, Kenneth Shinozuka, Joseph P Barsuglia
Abstract Ibogaine has shown early therapeutic promise for substance use disorders (SUD) and post-traumatic stress disorder in veterans, but concerns about treatment-associated cardiac arrhythmia and death have constrained clinical development. Whether this risk is uniform across indications or concentrated in specific populations is unknown. We conducted a retrospective multisite study of...
Journal of Psychoactive Drugs
June 17, 2026
F. van Dalen, Stephan Tap, S. D. Venema et al.
Psychedelic-assisted therapy (PAT) is increasingly recognized as a potential novel treatment for substance use disorder (SUD). As evidence continues to grow, the successful implementation of this modality into clinical practice will depend significantly on the perceptions and attitudes of mental healthcare professionals. Accordingly, a systematic review was conducted to provide a comprehensive...
International Journal for Research in Applied Science and Engineering Technology
June 14, 2026
Himali Upadhyay
Designer drugs or Novel Psychoactive Substances (NPSs) are synthetic compounds developed to mimic the pharmacological effects of controlled substances, but circumventing legal restrictions. The swift appearance of these compounds has become a significant concern to the global public health and forensic science owing to their increasing abuse potential, unpredictable toxicity, and continuous...
Journal of Psychedelic Studies
June 12, 2026
Zuzana Postránecká, Matyáš Lucký, Viktor Mravčík et al.
Abstract The Czech Republic, like many European countries, continues to face significant challenges in treating substance use disorders (SUDs), with high relapse rates and complex comorbidities often linked to trauma and mental illness. Psychedelic-assisted psychotherapy (PAP) has re-emerged internationally as a promising therapeutic modality, although available evidence remains heterogeneous...
Current Addiction Reports
June 11, 2026
Paul S. Regier
Purpose of Review: Neuroscientific models of addiction have evolved over the past four decades from single-circuit dopamine frameworks to dual-process, tripartite, and multidimensional accounts. Despite these advances, existing models incompletely account for the lived experience of addiction and for developmental, social, and mental-health factors that contribute to heterogeneity in risk and...
Psychopharmacology
June 10, 2026
Julian Kirsch, Christopher Poppe, Anne Beck et al.
BACKGROUND: Alcohol use disorder (AUD) remains a major global health concern, with high morbidity and mortality and limited long-term treatment success. Psychedelic therapy has re-emerged as a potential novel intervention for AUD, yet little is known about how affected individuals perceive such treatments. METHODS: This mixed-method study explored attitudes and perceptions of psychedelic...
Open MIND
June 1, 2026
Kellie Elkrief
Les troubles liés à l’usage de substances (TUS) touchent environ 2 % de la population mondiale et sont associés à une morbidité importante ainsi qu’à un risque de rechute élevé. Les envies impérieuses (le craving), définies comme une envie intense de consommer une substance, constituent une caractéristique centrale et transdiagnostique des TUS et représentent un prédicteur clé de rechute. Les...
Addictive behaviors
June 1, 2026
Sebastian Ehmann, Nathan M. Hager, Paul S. Regier et al.
Opioid use disorder (OUD) remains a major public health crisis in the United States, with mental health disorders substantially increasing risk severity. Emerging evidence suggests psychedelics may relate to reduced OUD risk. This exploratory study examined associations between lifetime psychedelic use and OUD severity and tested whether these associations varied by mental health impairment....
Addictive behaviors reports
June 1, 2026
Fares Qeadan, Shanti O'Neil
1 citation
Ketamine is increasingly used in clinical settings for mental health and pain management, yet its misuse poses public health risks. While prior studies have examined ketamine trends, few have explored its use among individuals receiving treatment for substance use disorders (SUD). Using 2021-2023 data from the National Survey on Drug Use and Health (NSDUH), we analyzed the association between...